Roberts Glore & CO Inc Abb Vie Inc. Transaction History

Roberts Glore & CO Inc

$341 Million
Q3 2024

A detailed history of Roberts Glore & CO Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Roberts Glore & CO Inc holds 30,442 shares of ABBV stock, worth $5.35 Million. This represents 1.76% of its overall portfolio holdings.

Number of Shares

30,442

Previous 32,850 7.33%

Holding current value

$5.35 Million

Previous $5.63 Million 6.69%

% of portfolio

1.76%

Previous 1.72%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $394,526 - $479,986	-2,408 Reduced 7.33%	30,442 $6.01 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $113,615 - $132,677	-734 Reduced 2.19%	32,850 $5.63 Million
Q1 2024 May 09, 2024	SELL	$159.82 - $182.1 $945,015 - $1.08 Million	-5,913 Reduced 14.97%	33,584 $6.12 Million
Q4 2023 Feb 12, 2024	SELL	$137.6 - $154.97 $827,939 - $932,454	-6,017 Reduced 13.22%	39,497 $6.12 Million
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $84,295 - $97,584	-631 Reduced 1.37%	45,514 $6.78 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $195,849 - $243,722	-1,478 Reduced 3.1%	46,145 $6.22 Million
Q1 2023 May 08, 2023	SELL	$144.61 - $166.54 $110,048 - $126,736	-761 Reduced 1.57%	47,623 $7.59 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $729,585 - $874,964	-5,275 Reduced 9.83%	48,384 $7.82 Million
Q3 2022 Nov 07, 2022	SELL	$134.21 - $153.93 $234,062 - $268,453	-1,744 Reduced 3.15%	53,659 $7.2 Million
Q2 2022 Aug 11, 2022	SELL	$137.62 - $174.96 $564,104 - $717,161	-4,099 Reduced 6.89%	55,403 $8.49 Million
Q1 2022 May 02, 2022	SELL	$131.98 - $163.75 $10.6 Million - $13.1 Million	-79,979 Reduced 57.34%	59,502 $9.65 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $7.19 Million - $9.1 Million	66,929 Added 92.25%	139,481 $18.9 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $130,659 - $148,317	-1,228 Reduced 1.66%	72,552 $7.83 Million
Q2 2021 Aug 10, 2021	SELL	$105.21 - $117.21 $236,932 - $263,956	-2,252 Reduced 2.96%	73,780 $8.31 Million
Q1 2021 May 06, 2021	SELL	$102.3 - $112.62 $268,128 - $295,177	-2,621 Reduced 3.33%	76,032 $8.23 Million
Q4 2020 Feb 09, 2021	SELL	$80.49 - $108.67 $5,151 - $6,954	-64 Reduced 0.08%	78,653 $8.43 Million
Q3 2020 Nov 06, 2020	BUY	$85.91 - $100.83 $601 - $705	7 Added 0.01%	78,717 $6.89 Million
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $273,963 - $366,604	-3,734 Reduced 4.53%	78,710 $7.73 Million
Q1 2020 May 11, 2020	SELL	$64.5 - $97.79 $4,257 - $6,454	-66 Reduced 0.08%	82,444 $6.28 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $4.14 Million - $5.18 Million	57,378 Added 228.31%	82,510 $7.31 Million
Q3 2019 Nov 08, 2019	SELL	$62.98 - $75.72 $4,660 - $5,603	-74 Reduced 0.29%	25,132 $1.9 Million
Q2 2019 Aug 09, 2019	SELL	$65.7 - $83.98 $657 - $839	-10 Reduced 0.04%	25,206 $1.83 Million
Q1 2019 May 14, 2019	SELL	$77.14 - $90.79 $3,779 - $4,448	-49 Reduced 0.19%	25,216 $2.03 Million
Q4 2018 Feb 08, 2019	SELL	$77.85 - $96.01 $11,210 - $13,825	-144 Reduced 0.57%	25,265 $2.33 Million
Q3 2018 Nov 09, 2018	BUY	$88.91 - $98.84 $19,382 - $21,547	218 Added 0.87%	25,409 $2.4 Million
Q2 2018 Aug 10, 2018	SELL	$89.78 - $106.23 $20,200 - $23,901	-225 Reduced 0.89%	25,191 $2.33 Million
Q1 2018 May 08, 2018	BUY	$92.01 - $123.21 $2,484 - $3,326	27 Added 0.11%	25,416 $2.41 Million
Q4 2017 Feb 09, 2018	SELL	$89.56 - $98.21 $13,523 - $14,829	-151 Reduced 0.59%	25,389 $2.46 Million
Q3 2017 Nov 08, 2017	SELL	$69.85 - $89.22 $22,631 - $28,907	-324 Reduced 1.25%	25,540 $2.27 Million
Q2 2017 Aug 15, 2017	BUY	N/A	25,864	25,864 $1.88 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.

Account

Roberts Glore & CO Inc Abb Vie Inc. Transaction History